Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JD010 in Adult Relapsed or Refractory B-cell Malignancies
NCT05645601Phase 1Unknown
- Sponsor
- Academy of Military Medical Sciences
- Start
- Dec 2022
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JD010 in B-cell hematologic malignancies, sponsored by Academy of Military Medical Sciences. Primary endpoints: Dose Limiting Toxicities at 1 month, Treatment-related Adverse Events at 3 months and 1 more. Status: unknown.
02
Drugs
JD010
03
Conditions
B-cell hematologic malignancies
Beyond the preview
Go deeper on NCT05645601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645601.